Thermo Fisher Scientific (TMO) Capital Expenditures (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Capital Expenditures for 18 consecutive years, with $376.0 million the latest figure, recorded in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $376.0 million, up 3.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 8.76% YoY), and the FY2025 annual result was $1.5 billion, up 8.93% from the prior year.
• Capital Expenditures was $376.0 million for Q1 2026 at Thermo Fisher Scientific, down from $465.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $640.0 million in Q2 2022 and troughed at $272.0 million in Q3 2024.
• Average Capital Expenditures over 5 years is $413.1 million, with a median of $404.0 million recorded in 2025.
• Year-over-year, Capital Expenditures slumped 43.87% in 2023 and soared 48.53% in 2025.
• Over 5 years, Capital Expenditures stood at $550.0 million in 2022, then dropped by 26.36% to $405.0 million in 2023, then rose by 18.52% to $480.0 million in 2024, then fell by 3.12% to $465.0 million in 2025, then dropped by 19.14% to $376.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $376.0 million in Q1 2026, $465.0 million in Q4 2025, and $404.0 million in Q3 2025.